Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer

Cheryl L. Rock, Shirley W. Flatt, Gail A. Laughlin, Ellen B. Gold, Cynthia A. Thomson, Loki Natarajan, Lovell A. Jones, Bette J. Caan, Marcia L. Stefanick, Richard A. Hajek, Wael K. Al-Delaimy, Frank Z. Stanczyk, John P. Pierce

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

Epidemiologic studies fairly consistently show in postmenopausal women that reproductive steroid hormones contribute to primary breast cancer risk, and this association is strongly supported by experimental studies using laboratory animals and model systems. Evidence linking sex hormone concentrations with risk for recurrence in women diagnosed with breast cancer is limited; however, beneficial effects of antiestrogenic therapy on recurrence-free survival suggest that these hormones affect progression and risk for recurrence. This study examined whether baseline serum concentrations of estradiol, testosterone, and sex hormone binding globulin were associated with recurrence-free survival in a nested case-control cohort of women from a randomized diet trial (Women's Healthy Eating and Living Study) who were followed for >7 years after diagnosis. In 153 case-control pairs of perimenopausal and postmenopausal women in this analysis, total estradiol [hazard ratio (HR), 1.41 per unit increase in log concentration; 95% confidence interval (95% CI), 1.01-1.97], bioavailable estradiol (HR, 1.26; 95% CI, 1.03-1.53), and free estradiol (HR, 1.31; 95% CI, 1.03-1.65) concentrations were significantly associated with risk for recurrence. Recurred women had an average total estradiol concentration that was double that of non-recurred women (22.7 versus 10.8 pg/mL; P = 0.05). Testosterone and sex hormone binding globulin concentrations did not differ between cases and controls and were not associated with risk for recurrence. Although genetic and metabolic factors likely modulate the relationship between circulating sex hormones and risk, results from this study provide evidence that higher serum estrogen concentration contributes to risk for recurrence in women diagnosed with early stage breast cancer.

Original languageEnglish (US)
Pages (from-to)614-620
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number3
DOIs
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Rock, C. L., Flatt, S. W., Laughlin, G. A., Gold, E. B., Thomson, C. A., Natarajan, L., Jones, L. A., Caan, B. J., Stefanick, M. L., Hajek, R. A., Al-Delaimy, W. K., Stanczyk, F. Z., & Pierce, J. P. (2008). Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiology Biomarkers and Prevention, 17(3), 614-620. https://doi.org/10.1158/1055-9965.EPI-07-0761